Pyrrolidine compounds and methods for selective inhibition...

Details Pyrrolidine compounds and methods for selective inhibition... Pyrrolidine compounds and methods for selective inhibition...

2008-01-08

2008-01-08

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S064000

Reexamination Certificate

active

07317109

ABSTRACT:
The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4572912 (1986-02-01), Yoshioka et al.
patent: 4681893 (1987-07-01), Roth
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5541204 (1996-07-01), Sher et al.
patent: 5574017 (1996-11-01), Gutheil
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5952301 (1999-09-01), Drucker
patent: 5952322 (1999-09-01), Hoover et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 5965532 (1999-10-01), Bachovchin
patent: 5998463 (1999-12-01), Hulin et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6040145 (2000-03-01), Huber et al.
patent: 6107317 (2000-08-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Villhauer
patent: 6166063 (2000-12-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6258597 (2001-07-01), Bachovchin et al.
patent: 6300314 (2001-10-01), Wallner et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6355614 (2002-03-01), Wallner
patent: 6380398 (2002-04-01), Kanstrup et al.
patent: 6395767 (2002-05-01), Robl et al.
patent: 6432969 (2002-08-01), Villhauer
patent: 6617340 (2003-09-01), Villhauer
patent: 6989402 (2006-01-01), Hangeland et al.
patent: 2003/0100563 (2003-05-01), Edmondson et al.
patent: 2003/0153509 (2003-08-01), Bachovchin et al.
patent: 2006/0258621 (2006-11-01), Campbell et al.
patent: 2006/0264401 (2006-11-01), Campbell et al.
patent: 2006/0276410 (2006-12-01), Campbell et al.
patent: 2007/0185061 (2007-08-01), Campbell
patent: 19616486 (1997-10-01), None
patent: 0818448 (1998-01-01), None
patent: 0896538 (1999-02-01), None
patent: 0978279 (2000-02-01), None
patent: 1041068 (2004-04-01), None
patent: WO-89/03223 (1989-04-01), None
patent: WO-91/16339 (1991-10-01), None
patent: WO-93/08259 (1993-04-01), None
patent: WO-93/10127 (1993-05-01), None
patent: WO-95/11689 (1995-05-01), None
patent: WO-95/15309 (1995-06-01), None
patent: WO-96/39384 (1996-12-01), None
patent: WO-96/39385 (1996-12-01), None
patent: WO-97/12613 (1997-04-01), None
patent: WO-97/12615 (1997-04-01), None
patent: WO-97/21993 (1997-06-01), None
patent: WO-98/00439 (1998-01-01), None
patent: WO-98/19998 (1998-05-01), None
patent: WO-98/50046 (1998-11-01), None
patent: WO-99/00353 (1999-01-01), None
patent: WO-99/03850 (1999-01-01), None
patent: WO-99/26659 (1999-06-01), None
patent: WO-99/38501 (1999-08-01), None
patent: WO-99/43663 (1999-09-01), None
patent: WO-00/34241 (2000-06-01), None
patent: WO-00/38722 (2000-07-01), None
patent: WO-00/47206 (2000-08-01), None
patent: WO-03/045228 (2003-06-01), None
patent: WO-03/045977 (2003-06-01), None
patent: WO-2004/004661 (2004-01-01), None
patent: WO-2005/047297 (2005-05-01), None
“Avasimibe: Treatment of Lipoprotein Disorders, ACAT Inhibitor”,Drugs of the Future 24(1), (1999), 9-15.
“International Search Report and Written Opinion for PTC Application No. PCT/US04/37820”, (Mar. 10, 2005), 9 pgs.
Bachovchin, W. W., et al., “Inhibition of IgA1 Proteinases fromNeisseria gonorrhoeaeandHemophilus influenzaeby Peptide Prolyl Boronic Acids”,Journal of Biological Chemistry, 265(7), (Mar. 5, 1990), 3738-3743.
Balkan, B., et al., “Improved Insulin Secretion and Oral Glucose Tolerance after In Vivo Inhibition of DPP-IV in Obese Zucker Rats”,Diabetologia, Suppl. 40, A131 Abstract, (1977),1 page, 511.
Biller, S. A., et al., “Communications to the Editor: Isoprenold (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”,Journal of Medicinal Chemistry, 31(10), (Oct. 1988), 1869-1871.
Biller, S. A., “Squalene Synthase Inhibitors”,Current Pharmaceutical Design, 2(1), (1996), 1-40.
Corey, E. J., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That “Presqualene Pyrophosphate” Is An Essential Intermediate on the Path to Squalene”,Journal of the American Chemical Society, 98(5), (1976), 1291-1293.
Coutts, S. J., “Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2Position of Xaa-boroPro Dipeptides”,J. Med. Chem. 39(10), (1996), 2087-2094.
Coutts, S. J., et al., “Two Efficient Methods for the Cleavage of Pinanediol boronate Esters Yielding the Free Boronic Acids”,Tetrahedron Letters, 35(29), (1994),5109-5112.
Deacon, C. F., et al., “Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects”,Diabetes, 44(9), Retrieved from the Internet: <http://gateway.ut.ovid.com.floyd.lib.umn.edu/gw2/ovidweb.cgi>, (1995), 1126-1131, (11 pgs.).
Deacon, C. F., et al., “Dipeptidyl Peptidase IV Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective”,Biochemical and Biophysical Research Communications 294, (2002), 1-4.
Demuth, H.-U. , et al., “Rebuttal to Deacon and Holst: “Metformin Effects on Dipeptidyl Peptidase IV Degradation of Glucagon-like Peptide-1” Versus “Dipeptidyl Peptidase Inhibition as an Approach to the Treatment and Prevention of Type 2 Diabetes: a Historical Perspective””,Biochemical and Biophysical Research Communications 296, (2002), 229-232, p. 229 only.
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”,Cardiovascular Drug Reviews, 16(1), (1998), 16-30.
Hara, S. , “Ileal Na=/blle Acid Cotransporter Inhibitors”,Drugs of the Future, 24(4), (1999), 425-430.
Hinke, S. A., et al., “Metformin Effects on Dipeptidyl-Peptidase IV Degradation of Glucagon-like Peptide-1”,Biochemical and Biophysical Research Communications 291, (2002), 1302-1308.
Holst, Jens J., et al., “Perspectives in Diabetes: Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes”,Diabetes, vol. 47, From the Department of Medical Physio

Affiliated with

Also associated with

Rating

Pyrrolidine compounds and methods for selective inhibition... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrrolidine compounds and methods for selective inhibition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine compounds and methods for selective inhibition... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2813277